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Diagnostic timeliness in adolescents and young adults with 
cancer: a cross-sectional analysis of the BRIGHTLIGHT cohort
Annie Herbert, Georgios Lyratzopoulos, Jeremy Whelan, Rachel M Taylor, Julie Barber, Faith Gibson, Lorna A Fern
Summary
Background Adolescents and young adults (AYAs) are thought to experience prolonged intervals to cancer diagnosis, 
but evidence quantifying this hypothesis and identifying high-risk patient subgroups is insufficient. We aimed to 
investigate diagnostic timeliness in a cohort of AYAs with incident cancers and to identify factors associated with 
variation in timeliness.
Methods We did a cross-sectional analysis of the BRIGHTLIGHT cohort, which included AYAs aged 12–24 years 
recruited within an average of 6 months from new primary cancer diagnosis from 96 National Health Service hospitals 
across England between July 1, 2012, and April 30, 2015. Participants completed structured, face-to-face interviews to 
provide information on their diagnostic experience (eg, month and year of symptom onset, number of consultations 
before referral to specialist care); demographic information was extracted from case report forms and date of diagnosis 
and cancer type from the national cancer registry. We analysed these data to assess patient interval (time from 
symptom onset to first presentation to a general practitioner [GP] or emergency department), the number of 
prereferral GP consultations, and the symptom onset-to-diagnosis interval (time from symptom onset to diagnosis) 
by patient characteristic and cancer site, and examined associations using multivariable regression models.
Findings Of 1114 participants recruited to the BRIGHTLIGHT cohort, 830 completed a face-to-face interview. Among 
participants with available information, 204 (27%) of 748 had a patient interval of more than a month and 242 (35%) of 
701 consulting a general practitioner had three or more prereferral consultations. The median symptom 
onset-to-diagnosis interval was 62 days (IQR 29–153). Compared with male AYAs, female AYAs were more likely to 
have three or more consultations (adjusted odds ratio [OR] 1·6 [95% CI 1·1–2·3], p=0·0093) and longer median 
symptom onset-to-diagnosis intervals (adjusted median interval longer by 24 days [95% CI 11–37], p=0·0005). Patients 
with lymphoma or bone tumours (adjusted OR 1·2 [95% CI 0·6–2·1] compared with lymphoma) were most likely to 
have three or more consultations and those with melanoma least likely (0·2 [0·1–0·7] compared with lymphoma). 
The adjusted median symptom onset-to-diagnosis intervals were longest in AYAs with bone tumours (51 days [95% CI 
29–73] longer than for lymphoma) and shortest in those with leukaemia (33 days [17–49] shorter than for lymphoma).
Interpretation The findings provide a benchmark for diagnostic timeliness in young people with cancer and help to 
identify subgroups at higher risk of a prolonged diagnostic journey. Further research is needed to understand reasons 
for these findings and to prioritise and stratify early diagnosis initiatives for AYAs.
Funding National Institute for Health Research, Teenage Cancer Trust, and Cancer Research UK.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Cancer is the leading cause of disease-related death for 
adolescents and young adults (AYAs) in high-income 
countries.1 The lower age of AYAs is typically around 
13 years but the upper range (of young adults) varies 
depending on jurisdiction from 24 years in the UK to 
39 years in the USA.1 Improvements in survival for this 
population have lagged behind both children and older 
adults,2 probably as a result of distinct cancer and host 
biology, historically limited support for research 
combined with barriers to accessing existing studies, 
and prolonged pathways to diagnosis in this age group.3,4
Most cancers are diagnosed after symptom onset.5 Some 
evidence suggests that AYAs experience a longer time 
from symptom onset to diagnosis than children and older 
adults.4,6–9 However, the evidence is difficult to interpret 
and inconclusive because comparable studies are rare. 
Prolonged intervals to diagnosis can adversely affect 
clinical outcomes, decrease confidence of patients and 
parents in their doctors, and are associated with a poor 
experience of subsequent cancer care.10,11 Nonetheless, 
diagnostic timeliness in AYAs is not well quantified and 
the identification of high-risk groups remains elusive.
Contributing factors to prolonged diagnostic intervals 
are likely to be multifactorial.12 Young people have poor 
knowledge of AYA cancers and their potential symptoms.13 
In primary care, cancer suspicion in AYAs is 
understandably low because cancer is rare in this age 
group and a general practitioner (GP) might see only one 
AYA with cancer in their career. This is further 
complicated because symptoms and signs can be 
attributed to other more common illnesses due to the 
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low positive predictive value of alarm symptoms in young 
people.14 For example, the reported positive predictive 
value of neck lump or mass for lymphoma (0·5%) would 
translate to five lymphoma diagnoses for every 1000 AYAs 
consulting with this symptom.14 Early recognition of 
cancer is key to timely treatment and can improve 
psychosocial and clinical outcomes.15 Such improvements 
are crucial in view of the potential societal and economic 
consequences of premature morbidity and mortality in 
young people with cancer.
We aimed to investigate diagnostic timeliness of cancer 
in a cohort of young people to identify factors associated 
with prolonged diagnostic journeys and generate 
evidence to inform interventions supporting earlier 
diagnosis and improvement of subsequent outcomes.
Methods
Study design and participants
We did a cross-sectional analysis of the BRIGHTLIGHT 
cohort. BRIGHTLIGHT is a programme of research 
assessing specialist care for young people with cancer in 
England.16 This project involves data derived from patient 
reports enriched by patient-level information from case 
report forms completed by recruiting National Health 
Service (NHS) clinical treatment teams in addition to 
diagnosis (cancer site) and diagnosis date data by the 
National Cancer Registration and Analysis Service of 
Public Health England.
The BRIGHTLIGHT programme recruited participants 
within a few months of cancer diagnosis from 96 NHS 
Trust hospitals across England, which deliver free 
universal health care to all patients in their geographical 
catchment. Treatment teams identified and recruited 
patients aged 13–24 years with any new primary cancer 
diagnosis between July 1, 2012, and April 30, 2015. 
Patients excluded were those unable to complete the 
survey, unable to give consent, or facing imminent death. 
Young people serving a custodial sentence were also 
excluded due to the impracticalities of obtaining consent. 
BRIGHTLIGHT was approved by London-
Bloomsbury Research Ethics Committee (reference 
11/LO/1718). In addition to their survey data, young 
Research in context
Evidence before this study
We searched MEDLINE/PubMed for studies published in any 
language between database inception and Oct 30, 2017, 
investigating diagnostic intervals and prereferral consultations in 
adolescents and young adults (AYA) aged 13–24 years with 
cancer, using the search terms: “intervals”, “diagnosis”, “time to 
diagnosis”, “delay”, “cancer”, “adolescents”, “teenagers”, and 
“young adults”. Additionally, we searched for papers by 
researchers and institutions that we knew had published in the 
field. We identified a systematic review on diagnostic intervals in 
children with cancer, and a review on diagnostic intervals in both 
children and young adults with cancer, including 32 studies 
reporting different measures or markers of diagnostic timeliness. 
The review in children and young adults included a 
single-institution, US study reporting total diagnostic intervals 
(from presentation to diagnosis) in patients aged 15–29 years 
with selected cancer types. We also identified a scoping review 
and five relevant studies: two studies used routine administrative 
data to detail primary-care use in young people before diagnosis, 
and the remaining three were single-centre studies that collected 
data through internal medical record review. Overall, evidence 
regarding diagnostic timeliness for AYAs is insufficient and 
heterogeneous because young people aged 13–24 years were 
usually included in studies of children (in which most were 
younger than 15 years) or older adults (in which most were aged 
50 years or older). Furthermore, the range of cancer types 
occurring in AYAs is distinct from those found in children and 
older adults, and thus the data reported are chiefly related to 
cancer types that are less relevant to AYAs. Additionally, because 
of the unique nature of health-care use and the range of disease 
occurring in AYAs, extrapolations from data on children or older 
adults must be viewed with caution.
Added value of this study
To our knowledge, our study is the first to solely focus on 
adolescents and young adults aged 13–24 years with any cancer 
site, and our cohort is currently the largest of AYA patients with 
cancer with both patient-reported data and clinical data. 
All participants were recruited from a range of hospitals (some of 
which were AYA Principal Treatment Centres) and interviews 
were done within an average of 6 months of diagnosis, limiting 
the potential for recall bias. Furthermore, for the first time we 
examined variation in diagnostic timeliness by 
sociodemographic characteristic and identify subgroups at 
increased risk of prolonged diagnostic intervals. In particular, AYA 
patients with melanoma are most likely to have long patient 
intervals (time from symptom onset to first health-care 
presentation), and female AYAs are more likely to have multiple 
general practitioner consultations before referral to a cancer 
specialist than male AYAs; AYA patients with lymphoma or bone 
cancer (both common cancers in adolescence) are also more 
likely to have multiple general practitioner consultations before 
referral than AYA patients with other cancers.
Implications of all the available evidence
These results provide evidence for policy makers, clinicians, and 
researchers about subgroups of AYAs at increased risk of 
prolonged diagnostic experiences, either before or after 
presentation. The results therefore enable future targeting of 
public health education or health-care interventions, and can be 
used to guide the development of new diagnostic care services 
and diagnostic technology innovations for AYA patients with new 
symptoms. We also show the feasibility of studying diagnostic 
timeliness in this age group on the basis of self-reports, which 
might enable routine future repeat surveys internationally.
Articles
182 www.thelancet.com/child-adolescent   Vol 2   March 2018
people also gave written informed consent for clinical 
information to be extracted from their medical records; 
additional data were obtained from the Office for Data 
Release at Public Health England following Section 
251 approval from the Confidentiality Advisory Group 
(reference ECC 8-05(d)/2011).
Procedures
Young people’s experience of cancer diagnosis was 
captured through structured, face-to-face interviews. 
Survey instrument development has been previously 
described.17 The overall survey instrument consists of 
15 domains identified by young people during 
BRIGHTLIGHT feasibility work as important in their 
cancer care experience, including experience before and 
during diagnosis.17 The survey provider (Ipsos MORI) 
contacted participants to do the interview in a location of 
the patient’s preference, mainly in their home. Questions 
were read out by the interviewer and answered from a 
list, with options for free text and for relevant dates. 
Patients answered questions about diagnostic events and 
intervals between their reported symptom onset and 
cancer diagnosis.
Sex, age at diagnosis, residential postcode (matched to 
Local Super Output Area and used to derive Index of 
Multiple Deprivation 2015 scores), and self-reported 
ethnicity were extracted from case report forms. 
Information on date of diagnosis and cancer type was 
extracted from the national cancer registry.
Outcomes and exposure variables
We used five survey questions and diagnosis date from 
the cancer registry to define two interval measures and a 
proxy marker of diagnostic timeliness (figure 1; appendix) 
in accordance with an international consensus statement 
and previous work on related measures: the patient 
interval (from symptom onset to first presentation to a GP 
or the emergency department), three or more GP 
consultations before referral to specialist services 
(restricted to patients who reported to have consulted with 
a GP), and the symptom onset-to-diagnosis interval.18–20
Exposure variables used in the analysis were sex, age at 
diagnosis (grouped as 12–15 years, 16–18 years, and 
19–24 years on the basis of recognised groupings of 
children and younger adolescents vs adolescents vs young 
adults),21 deprivation (grouped according to Index of 
Multiple Deprivation quintiles), ethnicity (white, black, 
Chinese, Asian, mixed, and other; grouped as white vs 
non-white), marital status (married or civil partnership, 
cohabiting, single, and divorced; grouped as married, 
civil partnership, or cohabiting vs single or divorced), and 
employment status (education, working full-time or 
part-time, other work [apprentice, internship, or 
voluntary], not seeking work, unemployed, and long-term 
sick). These exposure variables were selected because of 
their likely association with diagnostic timeliness as 
previously described by Walter and colleagues.22
We used Birch’s morphology-based classification for 
AYA cancers, which is based on the International 
Classification of Diseases, to better reflect cancer 
incidence patterns in young people.23 Groups comprised 
leukaemia; lymphoma; CNS and other intracranial 
and intraspinal neoplasms (CNS); osseous and 
chondromatous neoplasms, Ewing’s tumour, and other 
neoplasms of bone (bone tumours); soft tissue sarcomas; 
germ-cell and trophoblastic neoplasms (germ-cell 
tumours); melanoma and skin carcinoma; carcinomas 
(except of skin); and miscellaneous specified neoplasms 
not elsewhere classified and unspecified malignant 
neoplasms not elsewhere classified (grouped as 
unclassified or unspecified).
Statistical analyses
Because this study comprised secondary data analyses, 
no sample size calculations were done. We calculated 
descriptive statistics for each outcome, overall and by 
exposure variable. For patient interval, we reported 
numbers and proportions of patients for different binary 
interval cutoffs. We also described the numbers and 
proportions of patients with three or more prereferral 
GP consultations as it is associated with the length of 
primary care interval.19 Because the symptom onset-to-
diagnosis interval was a continuous variable (number of 
days), we reported descriptive statistics as 10th, 25th, 
50th, 75th, and 90th centiles.
We additionally fitted multivariable regression models 
including all exposures as independent variables to 
account for potential confounding of crude associations 
by other variables, including all patients with complete 
information on outcome and exposure variables. The 
reference groups in these models were male; aged 
12–15 years; least deprived; white; lymphoma (as the 
largest group by cancer site); married, in a civil 
partnership, or cohabiting; and in education. We tested 
for variation across multivariable categorical variables 
using joint Wald tests. We did not study interactions 
between exposures because we deemed the sample size 
was not large enough to enable such informative analysis.
For the BRIGHTLIGHT survey 
see https://xip.uclb.com/i/
healthcare_tools/brightlight_
wave1.html
See Online for appendix
Figure 1: Outcome definitions and their relation to key aspects of the diagnostic process
Relevant survey items and data sources used to define each outcome (A–C) are detailed in the appendix. 
A&E=accident and emergency department. GP=general practitioner.
First noticed symptom First GP or A&E visit Diagnosis date
Patient interval
Using responses to survey questions about time from symptom onset to first presentation, and place of first 
presentation, among responders who indicated they first sought help from a GP or at A&E
Number of prereferral consultations
Using responses indicating that patients had seen a GP at least once, 
and the number of reported prereferral consultations
Symptom onset-to-diagnosis interval
Using responses to month or year of symptom (or symptoms) onset, and cancer registry diagnosis date 
A
B
C
Specialist referral
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For the two outcomes that were parameterised as 
categorical variables (ie, patient interval and prereferral GP 
consultations), we fitted multivariable logistic regression 
models. We categorised the patient interval as a binary 
variable (≤1 month vs >1 month), informed by previous 
relevant studies in adult patients.24,25 We opted for a 
1 month cutoff, deeming this long enough to be clinically 
important, and taking into consideration that public health 
education campaigns about awareness of cancer symptoms 
typically use a cutoff of 3 weeks or longer for duration of 
new symptoms. We treated the number of prereferral 
consultations as a binary outcome (<3 vs ≥3), consistent 
with public reporting conventions of the National Cancer 
Patient Experience Survey,26 and because some second 
appointments could reflect the need to review findings of 
investigations ordered at initial consultation.27
For the continuous outcome (symptom onset-to-
diagnosis interval), we fitted multivariable quantile 
regression models with robust SEs.28 Quantile regression 
allows modelling at different quantiles of the outcome 
where associations between exposure and outcome can 
differ; we chose this modelling approach given statistical 
evidence for heterogeneity of associations for cancer site 
(eg, for soft tissue sarcoma p=0·01) and employment 
status (eg, for long-term sick p=0·04) in our sample. 
Because the univariate analysis did not show any 
clinically important variation at shorter durations of the 
symptom onset-to-diagnosis interval (eg, at the 
10th centile), we fitted quantile regression to the 
90th centile and the median symptom onset-to-diagnosis 
interval (ie, the 50th centile).
We analysed data in Stata, version 13.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Among 1114 participants recruited to the BRIGHTLIGHT 
cohort, 830 completed a face-to-face interview. Reasons for 
dropout between giving consent and interview included 
early death, refusal, and illness; these participants were 
Participants (n=830)*
Sex
Male 453 (55%)
Female 377 (45%)
Age at diagnosis (years)
Median (IQR) 20 (17–22)
12–15† 115 (14%)
16–18 187 (23%)
19–24 528 (64%)
Index of Multiple Deprivation
First quintile (least deprived) 184 (22%)
Second quintile 136 (16%)
Third quintile 156 (19%)
Fourth quintile 182 (22%)
Fifth quintile (most deprived) 158 (19%)
Missing 14 (2%)
Ethnic group‡
White 730 (88%)
Black 15 (2%)
Asian 61 (7%)
Chinese 4 (<1%)
Mixed 14 (2%)
Other 6 (1%)
Cancer site§ (descending order of most common)
Lymphoma 266 (32%)
Germ-cell tumours¶ 156 (19%)
Leukaemia 105 (13%)
Carcinomas (non-skin) 100 (12%)
Bone cancer|| 79 (10%)
Soft tissue sarcomas 50 (6%)
CNS** 33 (4%)
Melanoma and skin 31 (4%)
Unclassified or unspecified 10 (1%)
(Table 1 continues in next column)
Participants (n=830)*
(Continued from previous column)
Marital status††
Married, civil partnership, or cohabiting 119 (14%)
Single or divorced 709 (85%)
Missing 2 (<1%)
Employment status‡‡
Education 274 (33%)
Working full or part time 257 (31%)
Other work (apprentice, internship, or 
voluntary)
17 (2%)
Not seeking work 125 (15%)
Unemployed 31 (4%)
Long-term sick 126 (15%)
Data are n (%), unless stated otherwise. Missing category proportions only 
shown where applicable. *Due to rounding, percentages do not always total 
100%. †Five patients were 12 years old. ‡For analytical purposes, ethnicity was 
subsequently grouped as white versus non-white. §For the 70 (8%) patients for 
whom it was not possible to link data to the cancer registry, cancer site was taken 
from the participant registration form and checked against the case report form 
submitted by the clinical team. ¶Germ-cell and trophoblastic neoplasms. 
||Osseous and chondromatous neoplasms, Ewing’s tumour, and other neoplasms 
of bone. **CNS and other intracranial and intraspinal neoplasms. ††103 patients 
who were younger than 16 years and missing a response were assumed to be 
single. ‡‡Employment status is based on response to the question “can you tell 
me what you’re doing at the moment?”, and on a selection of multiple choice 
answers in the BRIGHTLIGHT survey. There were 13 possible responses, grouped 
into these six categories. For the 57 (7%) patients who gave more than one 
response, the category for analysis was selected by discussion (RMT and JB) on 
the basis of hierarchical rules.
Table 1: Sociodemographic variables and cancer site
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All patients with complete patient interval data Regression analysis of patient interval >1 month*
N >2 weeks >1 month >3 months N Crude 
percentage
Crude OR 
(95% CI)
Adjusted OR 
(95% CI)
All patients 748 359 (48%) 204 (27%) 91 (12%) 737 204 (28%) NA NA
Sex
Male 419 195 (47%) 107 (26%) 48 (11%) 414 107 (26%) 1 (ref) 1 (ref)
Female 329 164 (50%) 97 (29%) 43 (13%) 323 97 (30%) 1·2 (0·9–1·7) 1·1 (0·8–1·6)
p value ·· ·· ·· ·· ·· ·· ·· 0·57
Age at diagnosis (years)
12–15 104 42 (40%) 22 (21%) 6 (6%) 100 22 (22%) 1 (ref) 1 (ref)
16–18 170 83 (49%) 46 (27%) 18 (11%) 169 46 (27%) 1·3 (0·7–2·3) 1·3 (0·7–2·5)
19–24 474 234 (49%) 136 (29%) 67 (14%) 468 136 (29%) 1·5 (0·9–2·5) 1·6 (0·8–3·1)
p value ·· ·· ·· ·· ·· ·· ·· 0·38
Index of Multiple Deprivation
First quintile (least deprived) 168 86 (51%) 49 (29%) 24 (14%) 168 49 (29%) 1 (ref) 1 (ref)
Second quintile 121 53 (44%) 36 (30%) 15 (12%) 121 36 (30%) 1·0 (0·6–1·7) 1·1 (0·7–1·9)
Third quintile 139 66 (47%) 40 (29%) 22 (16%) 139 40 (29%) 1·0 (0·6–1·6) 1·0 (0·6–1·7)
Fourth quintile 164 88 (54%) 44 (27%) 13 (8%) 164 44 (27%) 0·9 (0·6–1·5) 0·9 (0·5–1·5)
Fifth quintile (most deprived) 145 62 (43%) 35 (24%) 17 (12%) 145 35 (24%) 0·8 (0·5–1·3) 0·8 (0·5–1·4)
p value ·· ·· ·· ·· ·· ·· ·· 0·83
Ethnic group
White 657 321 (49%) 182 (28%) 84 (13%) 647 182 (28%) 1 (ref) 1 (ref)
Non-white 91 38 (42%) 22 (24%) 7 (8%) 90 22 (24%) 0·8 (0·5–1·3) 0·8 (0·5–1·4)
p value ·· ·· ·· ·· ·· ·· ·· 0·44
Cancer site
Lymphoma 248 125 (50%) 66 (27%) 33 (13%) 247 66 (27%) 1 (ref) 1 (ref)
Germ-cell tumours 147 66 (45%) 36 (24%) 17 (12%) 147 36 (24%) 0·9 (0·6–1·4) 0·9 (0·5–1·5)
Leukaemia 89 42 (47%) 22 (25%) 5 (6%) 84 22 (26%) 1·0 (0·6–1·8) 1·1 (0·6–1·9)
Carcinomas 87 43 (49%) 28 (32%) 13 (15%) 86 28 (33%) 1·3 (0·8–2·2) 1·2 (0·7–2·1)
Bone tumours 68 33 (49%) 17 (25%) 6 (9%) 65 17 (26%) 1·0 (0·5–1·9) 1·0 (0·5–2·0)
Soft tissue sarcomas 41 17 (41%) 13 (32%) 4 (10%) 40 13 (33%) 1·3 (0·6–2·7) 1·3 (0·6–2·7)
CNS 30 10 (33%) 5 (17%) 2 (7%) 30 5 (17%) 0·5 (0·2–1·4) 0·5 (0·2–1·5)
Melanoma 28 19 (68%) 14 (50%) 10 (36%) 28 14 (50%) 2·7 (1·2–6·0) 2·8 (1·3–6·4)
Unclassified or unspecified 10 4 (40%) 3 (30%) 1 (10%) 10 3 (30%) 1·2 (0·3–4·8) 1·2 (0·3–4·8)
p value ·· ·· ·· ·· ·· ·· ·· 0·30
Marital status
Married, civil partnership, or 
cohabiting
106 56 (53%) 35 (33%) 14 (13%) 105 35 (33%) 1 (ref) 1 (ref)
Single or divorced 642 303 (47%) 169 (26%) 77 (12%) 632 169 (27%) 0·7 (0·4–1·1) 0·8 (0·5–1·3)
p value ·· ·· ·· ·· ·· ·· ·· 0·39
Employment status
Education 249 115 (46%) 65 (26%) 28 (11%) 245 65 (27%) 1 (ref) 1 (ref)
Working full-time or part-time 231 112 (48%) 61 (26%) 29 (13%) 229 61 (27%) 1·0 (0·7–1·5) 0·7 (0·4–1·2)
Other work (apprentice, 
internship, or voluntary)
17 12 (71%) 8 (47%) 1 (6%) 16 8 (50%) 2·8 (1·0–7·8) 2·5 (0·9–7·1)
Not seeking work 107 56 (52%) 28 (26%) 13 (12%) 105 28 (27%) 1·0 (0·6–1·7) 0·9 (0·5–1·5)
Unemployed 28 9 (32%) 6 (21%) 4 (14%) 28 6 (21%) 0·8 (0·3–2·1) 0·6 (0·2–1·7)
Long-term sick 116 55 (47%) 36 (31%) 16 (14%) 114 36 (32%) 1·3 (0·8–2·1) 1·0 (0·5–1·8)
p value ·· ·· ·· ·· ·· ·· ·· 0·22
Data are n (%) unless stated otherwise. Patient interval defined as time from first symptom to presentation to a general practitioner or accident and emergency department. 
OR=odds ratio. NA=not applicable. *Patients with patient interval and covariate information.
Table 2: Associations of patient interval with sociodemographic variables and cancer site
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not atypical to those who remained in the study (appendix). 
The median age of participants interviewed was 20 years 
(IQR 17–22), 453 (55%) were male, and most were white 
(table 1). Five patients aged 12 years were recruited, 
because of discrepancies in dates of diagnosis between the 
recruiting centre and the cancer registry. We retained 
these patients in the study because they were very close to 
their 13th birthday at recruitment. Common cancer 
diagnoses were lymphoma, germ-cell tumours, leukaemia, 
carcinomas, and bone cancer (table 1). Information was 
complete for sex, age, and ethnicity, with low levels of 
missingness for other variables. The median time between 
diagnosis and interview was 185 days (IQR 161–220), and 
we did not find an association between the length of 
diagnosis-to-interview period and the three diagnostic 
timeliness measures assessed (appendix). The socio demo-
graphic characteristics and cancer sites of BRIGHTLIGHT 
participants were overall similar to incident AYA cancer 
cases. A full description of the BRIGHTLIGHT cohort 
will be reported separately.
754 of 830 participants reported first seeking help from 
a GP or an accident and emergency department; of these, 
six were excluded from analysis of patient interval 
because of missing outcome information. Among the 
remaining 748 patients, about half had an interval of 
more than 2 weeks, with about one-third having intervals 
of more than a month, and even fewer more than 3 months 
(table 2). Older patients (aged 19–24 years) or patients 
with melanoma had higher observed proportions of 
prolonged patient intervals than other patient groups 
(table 2). In multivariable regression analysis, the greatest 
degree of variation in the proportion of patients with a 
patient interval duration of more than a month was 
observed for cancer site and employment status, although 
without statistical evidence of significance. Compared 
with patients with lymphoma, those with melanoma were 
most likely to have a patient interval of more than a 
month (table 2; figure 2). About half of the patients in the 
other work (apprentice, internship, or voluntary) category 
had a patient interval of more than a month, although 
this estimate is based on small numbers (table 2).
Of 830 participants, 125 did not indicate that they had 
visited their GP prereferral, and four did not know their 
number of prereferral GP visits. After excluding these 
patients, 242 (35%) of 701 patients reported that they 
visited a GP three or more times (table 3). Larger 
proportions of patients who were female, white, 
diagnosed with lymphoma or bone tumours, or not 
seeking work or registered as long-term sick at the time 
of interview had three or more prereferral consultations 
(table 3). Among those aged 16–18 years, the observed 
proportion who visited a GP three or more times was 
slightly lower than that in younger or older AYAs. In 
multivariable analysis, there was significant variation in 
the proportion of patients with three or more consultations 
by sex and cancer site (table 3). Specifically, female AYAs 
were more likely to have three or more consultations than 
male AYAs, as were AYAs diagnosed with lymphoma or 
bone tumours compared with those with other cancers 
(table 3; figure 2). The cancer sites least associated with 
three or more prereferral consultations were melanoma, 
germ-cell tumours, and leukaemia (table 3; figure 2).
After excluding 27 participants because of incomplete 
outcome data, 803 patients had complete information on 
their symptom onset-to-diagnosis interval, with a median 
interval of 62 days (IQR 29–153) and a high degree of 
positive skew across centiles (table 4). Substantial 
variation was observed in the 50th (ie, median) and 
90th centiles of the symptom onset-to-diagnosis interval 
by cancer site and each sociodemographic variable except 
ethnic group (table 4). Cancer site was strongly associated 
with the length of symptom onset-to-diagnosis interval; 
the majority of this variation was around the 75th to 
90th centiles, in which longer symptom onset-to-diagnosis 
intervals were apparent for unclassified or unspecific 
neoplasms, soft tissue sarcomas, and bone tumours 
(appendix). In multivariable quantile regression, 
significant variation was seen in the 50th (p=0·0005) and 
90th (p=0·0034) centiles by sex and cancer site (table 4). 
The adjusted median symptom onset-to-diagnosis 
interval for female AYAs was longer than for male AYAs 
by 24 (95% CI 11–37) days. The longest median symptom 
onset-to-diagnosis intervals were observed in patients 
diagnosed with bone tumours (51 [29–73] days longer 
than for lymphoma) and the shortest in patients 
diagnosed with leukaemia (33 [17–49] days shorter than 
for lymphoma). Although no significant variation was 
seen in the length of the symptom onset-to-diagnosis 
Figure 2: Adjusted odds ratios of (A) patient interval >1 month and (B) three or more prereferral 
GP consultations, by cancer site
Error bars denote 95% CI. GP=general practitioner. Bone tumours=osseous and chondromatous neoplasms, 
Ewing’s tumour, and other neoplasms of bone. CNS=CNS and other intracranial and intraspinal neoplasms. 
Germ-cell tumours=germ-cell and trophoblastic neoplasms
.
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Descriptive statistics for all patients 
with complete outcome information
Regression analysis of three or more prereferral GP consultations† 
N n (%) N Crude percentage Crude OR (95% CI) Adjusted OR (95% CI)
All patients 701 242 (35%) 686 237 (35%) NA NA
Sex
Male 387 110 (28%) 378 106 (28%) 1 (ref) 1 (ref)
Female 314 132 (42%) 308 131 (43%) 1·9 (1·4–2·6) 1·6 (1·1–2·3)
p value ·· ·· ·· ·· ·· 0·0093
Age at diagnosis (years)
12–15 93 35 (38%) 89 34 (38%) 1 (ref) 1 (ref)
16–18 163 50 (31%) 160 49 (31%) 0·7 (0·4–1·2) 0·6 (0·4–1·2)
19–24 445 157 (35%) 437 154 (35%) 0·9 (0·6–1·4) 0·8 (0·4–1·4)
p value ·· ·· ·· ·· ·· 0·36
Index of Multiple Deprivation
First quintile (least deprived) 157 51 (32%) 157 51 (32%) 1 (ref) 1 (ref)
Second quintile 116 38 (33%) 114 38 (33%) 1·0 (0·6–1·7) 1·1 (0·7–2·0)
Third quintile 137 51 (37%) 137 51 (37%) 1·2 (0·7–1·9) 1·3 (0·8–2·2)
Fourth quintile 148 53 (36%) 148 53 (36%) 1·2 (0·7–1·9) 1·2 (0·7–2·0)
Fifth quintile (most deprived) 130 44 (34%) 130 44 (34%) 1·1 (0·7–1·8) 1·0 (0·6–1·8)
p value ·· ·· ·· ·· ·· 0·85
Ethnic group
White 618 218 (35%) 604 214 (35%) 1 (ref) 1 (ref)
Non-white 83 24 (29%) 82 23 (28%) 0·7 (0·4–1·2) 0·7 (0·4–1·2)
p value ·· ·· ·· ·· ·· 0·21
Cancer site
Lymphoma 231 108 (47%) 229 108 (47%) 1 (ref) 1 (ref)
Germ-cell tumours 131 26 (20%) 131 26 (20%) 0·3 (0·2–0·5) 0·3 (0·2–0·6)
Leukaemia 95 21 (22%) 89 19 (21%) 0·3 (0·2–0·5) 0·3 (0·2–0·5)
Carcinomas 84 33 (39%) 83 33 (40%) 0·7 (0·4–1·2) 0·6 (0·4–1·1)
Bone tumours 63 32 (51%) 60 30 (50%) 1·1 (0·6–1·9) 1·2 (0·6–2·1)
Soft tissue sarcomas 39 10 (26%) 36 9 (25%) 0·4 (0·2–0·9) 0·4 (0·2–0·9)
CNS 25 6 (24%) 25 6 (24%) 0·4 (0·2–1·0) 0·3 (0·1–0·8)
Melanoma 25 4 (16%) 25 4 (16%) 0·2 (0·1–0·6) 0·2 (0·1–0·7)
Unclassified or unspecified 8 2 (25%) 8 2 (25%) 0·4 (0·1–2·0) 0·4 (0·1–1·9)
p value ·· ·· ·· ·· ·· <0·0001
Marital status
Married, civil partnership, or cohabiting 97 33 (34%) 96 33 (34%) 1 (ref) 1 (ref)
Single or divorced 602 209 (35%) 590 204 (35%) 1·0 (0·6–1·6) 1·0 (0·6–1·7)
p value ·· ·· ·· ·· ·· 0·94
Employment status
Education 231 74 (32%) 225 72 (32%) 1 (ref) 1 (ref)
Working full-time or part-time 221 71 (32%) 218 70 (32%) 1·0 (0·7–1·5) 1·1 (0·7–1·9)
Other work (apprentice, internship, or 
voluntary)
15 5 (33%) 14 5 (36%) 1·2 (0·4–3·7) 1·2 (0·4–4·0)
Not seeking work 103 39 (38%) 101 38 (38%) 1·3 (0·8–2·1) 1·1 (0·6–1·9)
Unemployed 27 7 (26%) 27 7 (26%) 0·7 (0·3–1·7) 1·1 (0·4–3·0)
Long-term sick 104 46 (44%) 101 45 (45%) 1·7 (1·0–2·8) 1·9 (1·0–3·4)
p value ·· ·· ·· ·· ·· 0·40
GP=general practitioner. OR=odds ratio. NA=not applicable. *Restricted to patients who responded that they had both first sought help from the GP (QWHERE) and that they 
had visited the GP before being referred (QVISIT1); see appendix for details. †Patients with prereferral consultation and covariate information.
Table 3: Associations of three or more prereferral GP consultations with sociodemographic variables and cancer site*
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Descriptive statistics for all patients with complete 
symptom onset-to-diagnosis interval
Multivariable quantile regression estimates 
(n=789*)
N 10th 25th 50th 75th 90th 50th centile (median) 90th centile
Coefficient (intercept 
57·7 days; 95% CI)
Coefficient (intercept 
169·2 days; 95% CI)
All patients 803 2 29 62 153 307 NA NA
Sex
Male 439 2 22 58 123 235 1 (ref) 1 (ref)
Female 364 6 32 84 187 367 24 (11 to 37) 104 (34 to 173)
p value ·· ·· ·· ·· ·· ·· 0·0005 0·0034
Age at diagnosis (years)
12–15 114 1 25 50 100 215 1 (ref) 1 (ref)
16–18 179 1 17 60 152 322 6 (–7 to 19) 69 (–90 to 229)
19–24 510 4·5 32 70 166 340 17 (–2 to 35) 84 (–72 to 240)
p value ·· ·· ·· ·· ·· ·· 0·20 0·57
Index of Multiple Deprivation
First quintile (least deprived) 176 3 30 74·5 171·5 365 1 (ref) 1 (ref)
Second quintile 129 2 30 64 148 275 –6 (–26 to 14) –17 (–128 to 95)
Third quintile 155 1 26 56 150 371 –22 (–39 to –6) 47 (–63 to 157)
Fourth quintile 177 4 32 62 151 278 –7 (–24 to 10) 17 (–93 to 127)
Fifth quintile (most deprived) 153 4 24 60 148 305 –10 (–33 to 13) –10 (–117 to 97)
p value ·· ·· ·· ·· ·· ·· 0·040 0·65
Ethnic group
White 706 2 29 62 152 307 1 (ref) 1 (ref)
Non-white 97 1 29 68 155 338 12 (–14 to 38) –21 (–115 to 74)
p value ·· ·· ·· ·· ·· ·· 0·36 0·67
Cancer site
Lymphoma 256 5 32 67·5 159·5 338 1 (ref) 1 (ref)
Germ-cell tumours 153 3 23 57 101 182 –23 (–38 to –7) –67 (–152 to 19)
Leukaemia 103 0 15 33 78 161 –33 (–49 to –17) –65 (–183 to 52)
Carcinomas 97 1 32 99 188 367 12 (–25 to 49) –17 (–127 to 94)
Bone tumours 77 17 53 107 222 400 51 (29 to 73) 101 (–117 to 319)
Soft tissue sarcomas 43 1 46 78 211 502 14 (–7 to 36) 245 (145 to 345)
CNS 33 6 30 56 166 342 –1 (–33 to 31) 82 (–484 to 647)
Melanoma 31 1 8 89 219 259 6 (–57 to 69) –38 (–123 to 47)
Unclassified or unspecified 10 6 15 90·5 250 806·5 38 (–161 to 237) 92 (–1958 to 2141)
p value ·· ·· ·· ·· ·· ·· <0·0001 <0·0001
Marital status
Married, civil partnership, or cohabiting 114 14 33 78 185 383 1 (ref) 1 (ref)
Single or divorced 688 1 27 62 147·5 296 –12 (–39 to 15) 7 (–79 to 94)
p value ·· ·· ·· ·· ·· ·· 0·38 0·87
Employment status
Education 264 1 22 54 130 227 1 (ref) 1 (ref)
Working full-time or part-time 251 5 32 66 167 296 7 (–11 to 26) 4 (–72 to 80)
Other work (apprentice, intern, or 
voluntary)
17 19 32 100 151 381 35 (–14 to 85) 151 (–300 to 603)
Not seeking work 121 7 29 63 158 262 –12 (–30 to 6) –67 (–193 to 59)
Unemployed 28 1 18 60 125·5 215 2 (–39 to 44) –36 (–124 to 52)
Long-term sick 122 6 32 85·5 193 581 20 (–12 to 52) 222 (90 to 353)
p value ·· ·· ·· ·· ·· ·· 0·25 0·014
NA=not applicable. *Patients with symptom onset-to-diagnosis and covariate information.
Table 4: Associations of symptom onset-to-diagnosis interval with sociodemographic variables and cancer site
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interval at the 50th centile by employment status, this 
was the case at the 90th centile (table 4). Patients who 
were long-term sick had the longest adjusted 90th centile 
of symptom onset-to-diagnosis interval (222 [90–353] days 
longer than for those in education).
Discussion
We investigated diagnostic timeliness in AYAs with cancer 
and examined related variation by socio demographic 
characteristic and cancer site. Compared with male AYAs, 
female AYAs were more likely to have multiple prereferral 
GP consultations and longer median symptom-onset-to-
diagnosis intervals. Further study is needed to understand 
causes underlying these patterns. There were large 
variations by cancer site in all aspects of diagnostic 
timeliness studied. For example, AYAs with melanoma 
were most likely to wait longer than a month before 
seeking help about their symptoms, but, by contrast, were 
the least likely to have multiple prereferral consultations, 
consistent with the readily identifiable clinical features of 
this cancer. Patients with lymphoma or bone tumours 
were most likely to have multiple prereferral consultations, 
reflecting the often less specific presenting features and 
the greater diagnostic difficulty of these cancers. The 
median time from symptom onset to diagnosis was 
longest for bone tumours and shortest for leukaemia.
Comparison with existing scientific literature is 
difficult because studies focusing solely on AYAs are 
rare. This study is the largest one so far examining 
diagnostic timeliness in AYAs, which was found to be 
poorer than that reported for children or older adults 
with cancer.4,6,7,27,29 In the present study, among AYAs who 
consulted with their GP, about one in three had 
three or more prereferral consultations compared with 
substantially lower percentages reported previously for 
chiefly adult English patients with cancer (18–23%).27,29
We know of no comparable studies investigating 
diagnostic intervals across all cancer sites in AYA patients. 
Most previous studies had small study samples that were 
restricted to only some cancer sites, or combined data 
from AYAs with those of children or older adults. 
A systematic review of 32 studies summarising patient 
and diagnostic intervals in children and young people with 
cancer found only one study of 235 patients in the USA 
reporting exclusively on AYAs.30 The proportion of patients 
in our sample consulting their GP three or more times 
before a referral (35%) was similar to that reported for the 
youngest age group (16–24 years) of respondents to the 
2010 English Cancer Patient Experience Survey (42%).27
Our sample of more than 800 AYAs with high 
completeness of exposure data allowed us to study 
associations between diagnostic timeliness outcomes and 
sociodemographic and cancer site variables, after adjusting 
for potential confounding through multivariable 
regression. Survey participants were generally repre-
sentative of incident cancer cases, although brain tumours 
and melanoma were slightly under-represented and 
sarcomas over-represented in our sample (data not shown), 
which might reflect differences in the nature and frequency 
of contact of these patient groups with hospital services. 
For example, the management of melanoma is generally 
surgical and conducted by skin cancer teams, which are 
frequently not co-located with AYA services, and surgical 
centres for brain tumours are not always well linked with 
AYA services. Patient interviews were done relatively close 
to the time of diagnosis (on average within 6 months), 
minimising concerns about potential survivorship bias 
(whereby patient groups with high risk of mortality post-
diagnosis are under-represented among surveyed 
participants) or recall bias.
Despite substantial efforts, around 50% of patients 
eligible to participate in this study were not invited to 
take part because of professional and organisational 
barriers.31 As is common in population surveys, there 
was a degree of missing data for some outcomes. 
Although diagnostic timeliness in invited patients and in 
those analysed might differ, the patterns of variation in 
the studied outcomes by patient characteristic are 
unlikely to vary.32
Inaccuracies in the recall of first symptom are possible, 
the effect of which will vary by cancer site. For example, a 
young person might more easily recall first noticing a 
definitive skin lesion than symptoms such as fatigue or 
bone pain, which could partly be normalised by the 
patient, a family member, or a GP,33 and health-care 
contact might only be triggered after an accumulation of 
vague symptoms. Some evidence suggests that young 
people might wait until a threshold is reached, such as 
symptoms interfering with everyday life or unbearable 
pain, before seeking care.33 Such differences in recall 
could result in more accurate estimates about the 
diagnostic timeliness of cancer sites associated with 
specific symptoms, such as melanoma or male germ-cell 
cancers, and the potential for greater inaccuracy for 
cancer sites associated with symptoms of relatively low 
predictive value. Nevertheless, we observe sufficient 
evidence for variation by cancer site.
A limitation of our study is that some associations 
might have appeared significant by chance as a result of 
testing for multiple exposures. We nonetheless observed 
strong evidence (p values <0·01) for variation by sex and 
cancer site with respect to prereferral consultations and 
the length of the symptom onset-to-diagnosis interval, 
which minimises, although it does not preclude, concerns 
about chance associations due to multiple testing.
Although our study is the largest so far to examine 
diagnostic timeliness in AYAs, the number of categories in 
certain variables (eg, the number of cancer site groups, 
and therefore the number of cancer–sex–age–deprivation–
ethnicity strata in multivariable models) means that certain 
estimates of associations have low precision. In such 
circumstances, focusing on overall patterns of variation 
between categories rather than category-specific estimates 
is preferable. Notably, cancer is a heterogeneous disease, 
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and as we describe, diagnostic timeliness varies by cancer 
site. In our multivariable analysis, estimates for 
sociodemographic variables are adjusted for the cancer site 
case-mix in our sample; therefore, they represent an 
average effect of, for example, sex, on diagnostic timeliness 
across AYAs with any cancer site. In truth, the association 
with sex might vary between different cancer sites, but we 
have not been able to investigate interactions between 
different exposure variables on the outcomes of interest—
eg, whether the greater proportion of three or more 
prereferral consultations observed in female AYAs is the 
same across cancer sites or whether it varies between 
cancers.
Early diagnosis is a global priority in cancer control. 
Worldwide, 350 000 incident cancer cases per year are 
estimated in young people aged 15–29 years, and this is 
increasing.1,34 Reducing cancer-related disease burden and 
improving cancer outcomes in this age group is therefore 
a priority. However, earlier diagnosis as a potential strategy 
to improve outcomes has received little or no attention; 
consequently, little evidence exists currently upon which to 
base interventions. For the first time, within a group of 
cancers that are generally difficult to diagnose and rare, we 
have identified subgroups at higher risk of prolonged 
intervals to diagnosis. These findings present several 
opportunities for public health and health-care 
interventions aimed at shortening diagnostic intervals for 
AYAs, which can initially target female AYAs and those 
with symptoms suggestive of melanoma, lymphoma, and 
bone tumours. Longer time to help-seeking for melanoma 
symptoms mirrors findings from previous quantitative 
and qualitative studies in adult patients, which suggest 
that indicative skin changes are often normalised.24,33,35 
These data would lend support to awareness campaigns 
educating AYAs about melanoma risk and symptoms, 
particularly in view of its increasing incidence. Young 
people do consult with their GP for a range of reasons 
(eg, for contraception [in female AYAs] or infections), and 
these visits present opportunities to educate AYAs about 
cancer prevention and relevant symptoms. Further 
research is needed to investigate the psychological, 
sociological, and circum stantial factors contributing to 
timely presentation, referral, and diagnosis. The length of 
the patient interval might be associated with factors such 
as a lack of awareness of cancer symptoms among AYAs, 
reassurance by family and friends, inconvenience or 
competing priorities delaying making or attending GP 
appointments, or lack of experience of accessing the 
health-care system. Furthermore, symptoms are often 
initially attributed to other common illnesses or injuries by 
both patients and their GPs, particularly in view of the low 
risk of cancer in this age group.
Female AYAs and AYAs with lymphoma or bone tumours 
were more likely to experience multiple GP consultations 
before being referred for suspicion of cancer. This finding 
mirrors similar differences reported in older patients with 
cancer.27 For young people, symptoms initially might be 
falsely attributed to other common illnesses in young 
adults, such as musculoskeletal (including sports-related) 
or gynaecological complaints.36 This is supported by our 
findings that patients with melanoma and germ-cell 
tumours (including testicular cancer), which are typically 
associated with fairly specific symptoms that are easy to 
examine, were some of the least likely to consult multiple 
times. Although the prevalence of tumours among AYAs is 
relatively low,14,23 previous research in primary care records 
has estimated that the presence of head lump mass or 
neck or lymph node swelling increases the likelihood of 
lymphoma by 200–400 times, and any lump, mass, or 
swelling increases the likelihood of bone tumours or soft 
tissue sarcomas by around 80 times.14 Therefore, there is a 
need, not only for rapid referral for tests either to a 
secondary care clinician or to diagnostic service following 
such symptoms in AYAs, as per clinical guidelines,37 but 
also for new diagnostic technologies to aid GP 
decision making.
Although certain subgroups of AYAs are at increased 
risk of prolonged time intervals to diagnosis, the related 
effect on clinical and patient experience outcomes is yet 
to be fully understood. A systematic review20 of the 
associations between time to diagnosis or treatment and 
clinical outcomes encompassed patients aged 0–24 years 
as a single age group, without disaggregating the data by 
age. It reported mixed findings regarding stage at 
diagnosis and survival depending on cancer site and no 
studies investigating associations for patients with either 
of the two most common cancers in AYAs: lymphoma 
and germ-cell tumours. In addition to clinical and patient 
experience improvements, the societal gains associated 
with early diagnosis are likely to be substantial in view of 
the life-years lost or at risk in people diagnosed with 
cancer at an early age.
In summary, we have assessed patient-reported data on 
diagnostic timeliness in a large representative multicentre 
cohort of AYAs with cancer in England. We have identified 
subgroups at greater risk of prolonged intervals from 
symptom onset to presentation and diagnosis, in whom 
further research and early diagnosis interventions might 
be additionally targeted to maximise their effectiveness 
(ie, female AYAs and AYAs with symptoms or signs of 
melanoma, lymphoma, or bone tumours). Despite its 
rarity, early detection of cancer in AYAs warrants 
prioritisation because of the societal and economic gains 
that can result from improved survival and psychosocial 
outcomes in this group. However, because of the difficulty 
of diagnosing cancer in AYAs, innovations in diagnostic 
technologies (including point-of-care rule-out tests or 
algorithms to be used in primary care) also need to be 
developed and assessed.
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